← Back to Clinical Trials
Recruiting NCT07179757

NCT07179757 Clinical Outcomes and Quality of Life in Patients With Locally Advanced Vulvovaginal Cancers: Ambispective Registration Study.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07179757
Status Recruiting
Phase
Sponsor Tata Memorial Hospital
Condition Vulvo-vaginal Cancer
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2021-10-30
Primary Completion 2026-06-30

Eligibility & Interventions

Sex Female only
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2021-10-30 with a primary completion date of 2026-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The vaginal cancers are responsible for 2% of gynecological cancer while vulvar cancers account for 4 % of gynecological cancers. HPV 16 and 33 are most prevalent in vaginal cancers and account for more than half of cases HPV related vaginal cancer. However, adeqaute information is not there. Similarly, structured QOL data is not available for India. Therefore, in the proposed study we will like to systematically evaluate the patterns of relapse and disease outcomes in patients with vulvovaginal cancer treated with radiation (+/- chemotherapy). The therapeutic research in vulvo-vaginal cancers has been relatively slow and such structured registration databases can allow analysis of large number of patients to report on acute and late effect of treatment outcomes using CTCAE and QOL (EORTC QLQ C-30 and VU-34) in rare cancers. We hope that we will get help in identifying thrust areas for future research including prospective interventional trials through this study.

Eligibility Criteria

Inclusion Criteria: 1. All patients diagnosed with vulvo- vaginal cancer. 2. Patients treated with Radiation+/- chemotherapy+/-surgery from January 1, 2019- December 31, 2023. Exclusion Criteria: 1. Patients with Metastatic disease at the presentation. 2. Incomplete information on the EMR.

Contact & Investigator

Central Contact

Dr. Supriya Chopra

✉ supriyasastri@gmail.com

📞 +022-68735000

Frequently Asked Questions

Who can join the NCT07179757 clinical trial?

This trial is open to female participants only, studying Vulvo-vaginal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07179757 currently recruiting?

Yes, NCT07179757 is actively recruiting participants. Contact the research team at supriyasastri@gmail.com for enrollment information.

Where is the NCT07179757 trial being conducted?

This trial is being conducted at Mumbai, India.

Who is sponsoring the NCT07179757 clinical trial?

NCT07179757 is sponsored by Tata Memorial Hospital. The trial plans to enroll 200 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology